ARTICLE | Clinical News
AG-702 herpes simplex virus 2 vaccine: Began Phase I trial
November 12, 2001 8:00 AM UTC
Antigenics Inc. (AGEN), New York, N.Y. Product: AG-702 herpes simplex virus 2 (HSV-2) vaccine Business: Infectious diseases Therapeutic category: Immune stimulation Target: Immune cells Description: R...